China's Leading Vaccine Developer, Sinovac, Aims To Channel Expanding Earnings Into Acquisitions
This article was originally published in PharmAsia News
Executive Summary
BEIJING - While reporting a steep rise in profits for the second quarter of this year, the leadership of Chinese vaccine developer Sinovac Biotech said the cash-rich outfit is screening potential acquisition candidates across China
You may also be interested in...
Vaccine Maker Sinovac Enters Into Joint Venture In Chinese Coastal City Of Dalian
SHANGHAI - Flush with cash following strong earnings for the third quarter and rising sales of the seasonal influenza vaccine Anflu, Beijing-based Sinovac Biotech aims to expand operations by investing in a joint venture in the Northeastern coastal city of Dalian, the company announced Nov. 25
Vaccine Maker Sinovac Enters Into Joint Venture In Chinese Coastal City Of Dalian
SHANGHAI - Flush with cash following strong earnings for the third quarter and rising sales of the seasonal influenza vaccine Anflu, Beijing-based Sinovac Biotech aims to expand operations by investing in a joint venture in the Northeastern coastal city of Dalian, the company announced Nov. 25
China's Sinovac, With High-level Government Backing, Could Win Global Race To Market A/H1N1 Vaccine
BEIJING - With the strong support of China's central government and Beijing health authorities, leading vaccine maker Sinovac Biotech could become the first to cross the finish line in the worldwide race to produce a defense to the A/H1N1 pandemic